RNTX (Rein Therapeutics) Short Interest


RNTX Rein Therapeutics Inc RNTX
30 GF Score
Price $1.01
! 1 Warning Sign
View Full Analysis

What is Rein Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RNTX vs ATRA, OSTX, IBIO: Short Interest Comparison

For the Biotechnology subindustry, Rein Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rein Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Rein Therapeutics's Short Interest falls into.


RNTX
30GF Score
Rein Therapeutics Inc RNTX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rein Therapeutics Business Description

Address 12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
30GF Score

Get the complete analysis for RNTX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price